JNJ-55308942 explained

JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release.[1] [2] [3] It is developed by Janssen Pharmaceuticals for bipolar depression.[4]

See also

Notes and References

  1. Bhattacharya . Anindya . Lord . Brian . Grigoleit . Jan-Sebastian . He . Yingbo . Fraser . Ian . Campbell . Shannon N. . Taylor . Natalie . Aluisio . Leah . O’Connor . Jason C. . Papp . Mariusz . Chrovian . Christa . Carruthers . Nicholas . Lovenberg . Timothy W. . Letavic . Michael A. . Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia . Neuropsychopharmacology . December 2018 . 43 . 13 . 2586–2596 . 10.1038/s41386-018-0141-6 . 30026598 . 6224414 . 0893-133X.
  2. Bhattacharya . Anindya . Ceusters . Marc . Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders . Neuropsychopharmacology . January 2020 . 45 . 1 . 234–235 . 10.1038/s41386-019-0502-9 . 31477815 . 6879571 . 0893-133X.
  3. Kolb . Hartmuth C. . Barret . Olivier . Bhattacharya . Anindya . Chen . Gang . Constantinescu . Cristian . Huang . Chaofeng . Letavic . Michael . Tamagnan . Gilles . Xia . Chunfang A. . Zhang . Wei . Szardenings . Anna Katrin . Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of 18 F-JNJ-64413739, a PET Radioligand for P2X7 Receptors . Journal of Nuclear Medicine . August 2019 . 60 . 8 . 1154–1159 . 10.2967/jnumed.118.212696 . 30733317 . 73454130 . en . 0161-5505. free .
  4. Web site: CTG Labs - NCBI . clinicaltrials.gov . 27 November 2023.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "JNJ-55308942".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.